Arrowhead Pharmaceuticals Inc (ARWR)
18.54
+0.26
(+1.42%)
USD |
NASDAQ |
Nov 22, 16:00
18.53
-0.01
(-0.05%)
After-Hours: 20:00
Arrowhead Pharmaceuticals Net Income (Quarterly): -170.79M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -170.79M |
| March 31, 2024 | -125.30M |
| December 31, 2023 | -132.86M |
| September 30, 2023 | -109.68M |
| June 30, 2023 | -102.95M |
| March 31, 2023 | 48.68M |
| December 31, 2022 | -41.32M |
| September 30, 2022 | -85.51M |
| June 30, 2022 | -72.05M |
| March 31, 2022 | 44.37M |
| December 31, 2021 | -62.87M |
| September 30, 2021 | -63.37M |
| June 30, 2021 | -29.92M |
| March 31, 2021 | -26.82M |
| December 31, 2020 | -20.73M |
| September 30, 2020 | -48.43M |
| June 30, 2020 | -13.61M |
| March 31, 2020 | -19.84M |
| December 31, 2019 | -2.673M |
| September 30, 2019 | 11.71M |
| June 30, 2019 | 20.34M |
| March 31, 2019 | 23.90M |
| December 31, 2018 | 12.04M |
| September 30, 2018 | -10.76M |
| June 30, 2018 | -15.61M |
| Date | Value |
|---|---|
| March 31, 2018 | -14.88M |
| December 31, 2017 | -13.20M |
| September 30, 2017 | -10.73M |
| June 30, 2017 | -5.520M |
| March 31, 2017 | -6.043M |
| December 31, 2016 | -12.09M |
| September 30, 2016 | -22.22M |
| June 30, 2016 | -19.42M |
| March 31, 2016 | -20.82M |
| December 31, 2015 | -19.26M |
| September 30, 2015 | -24.74M |
| June 30, 2015 | -15.94M |
| March 31, 2015 | -28.68M |
| December 31, 2014 | -22.58M |
| September 30, 2014 | -22.43M |
| June 30, 2014 | -11.63M |
| March 31, 2014 | -13.94M |
| December 31, 2013 | -10.63M |
| September 30, 2013 | -13.69M |
| June 30, 2013 | -6.079M |
| March 31, 2013 | -6.758M |
| December 31, 2012 | -4.614M |
| September 30, 2012 | -5.314M |
| June 30, 2012 | -7.992M |
| March 31, 2012 | -5.335M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-170.79M
Minimum
Jun 2024
48.68M
Maximum
Mar 2023
-54.51M
Average
-48.43M
Median
Sep 2020
Net Income (Quarterly) Benchmarks
| Vaxcyte Inc | -103.12M |
| CEL-SCI Corp | -6.857M |
| AIM ImmunoTech Inc | -3.70M |
| IGC Pharma Inc | -1.717M |
| NovaBay Pharmaceuticals Inc | -1.212M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 176.14M |
| EPS Diluted (Quarterly) | -1.38 |
| Enterprise Value | 1.879B |
| Earnings Yield | -25.13% |
| Normalized Earnings Yield | -14.94 |